[go: up one dir, main page]

PE20070353A1 - Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol - Google Patents

Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol

Info

Publication number
PE20070353A1
PE20070353A1 PE2006000973A PE2006000973A PE20070353A1 PE 20070353 A1 PE20070353 A1 PE 20070353A1 PE 2006000973 A PE2006000973 A PE 2006000973A PE 2006000973 A PE2006000973 A PE 2006000973A PE 20070353 A1 PE20070353 A1 PE 20070353A1
Authority
PE
Peru
Prior art keywords
acid
hfc
salbutamol
citrate
hydrochloride
Prior art date
Application number
PE2006000973A
Other languages
English (en)
Inventor
Friedrich Schmidt
Mariola Mann
Holger Memmesheimer
Michael Cope
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20070353A1 publication Critical patent/PE20070353A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION DE UNA DISOLUCION PARA AEROSOL QUE COMPRENDE: A) SAL DE SALBUTAMOL DE ADICION DE ACIDO (HIDROCLORURO O CITRATO) COMPRENDIDA ENTRE 0,001-1%; B) UN PROPELENTE DE HFC SELECCIONADO ENTRE HFC-134(a), HFC-227, HFC-134 Y MEZCLAS DE LOS MISMOS; C) UN DISOLVENTE CONJUNTO; D) UN ACIDO INORGANICO TALES COMO HCl, ACIDO SULFURICO, ACIDO NITRICO, ACIDO FOSFORICO, O UNO ORGANICO TALES COMO ACIDO ASCORBICO, ACIDO CITRICO, ACIDO LACTICO, ACIDO MALICO, ENTRE OTROS. ADICIONALMENTE PUEDE CONTENER UNA SUSTANCIA FARMACOLOGICA TAL COMO BROMURO DE IPRATROPIO. DICHA FORMULACION ES ADECUADA PARA SU ADMINISTRACION MEDIANTE INHALADORES DE DOSIS MEDIA EN EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
PE2006000973A 2005-08-12 2006-08-10 Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol PE20070353A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05017599 2005-08-12

Publications (1)

Publication Number Publication Date
PE20070353A1 true PE20070353A1 (es) 2007-04-19

Family

ID=35564491

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000973A PE20070353A1 (es) 2005-08-12 2006-08-10 Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol

Country Status (6)

Country Link
US (1) US20070041911A1 (es)
AR (1) AR057745A1 (es)
PE (1) PE20070353A1 (es)
TW (1) TW200800141A (es)
UY (1) UY29740A1 (es)
WO (1) WO2007020204A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
ES2796177T5 (es) 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
CN109715160A (zh) 2016-09-19 2019-05-03 墨西哥氟石股份公司 药物组合物
AU2017328910B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
ES2968453T3 (es) 2016-09-19 2024-05-09 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
WO2019236559A1 (en) * 2018-06-04 2019-12-12 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
FR3130554B1 (fr) 2021-12-20 2024-10-18 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
CA2111003A1 (en) * 1991-06-10 1992-12-23 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
JP2003221335A (ja) * 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
CN1216600C (zh) * 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
CN1228045C (zh) * 2003-11-03 2005-11-23 王立强 口腔速崩速溶片制剂及其制备方法
GB0406069D0 (en) * 2004-03-17 2004-04-21 Thompson James Process

Also Published As

Publication number Publication date
US20070041911A1 (en) 2007-02-22
AR057745A1 (es) 2007-12-12
WO2007020204A2 (en) 2007-02-22
TW200800141A (en) 2008-01-01
WO2007020204A3 (en) 2007-06-07
UY29740A1 (es) 2007-03-30

Similar Documents

Publication Publication Date Title
AR101593A2 (es) Formulación superfina de formoterol
AR038641A1 (es) Formulacion superfina de formoterol
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
MX2021009476A (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
PE20080204A1 (es) Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista
DE60114571D1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
PE20070353A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
ME02342B (me) Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom
UY30139A1 (es) Formulacion farmaceuica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
AR040450A1 (es) Formulacion superfina de salmeterol
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
DK2089008T3 (da) Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator
CO2023004162A2 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
NO20074854L (no) Farmasoytiske aerosolformuleringer for komprimerte, utmalte doseinhalatorer omfattende et sekvestreringsmiddel
ES2542177T3 (es) Uso de osmolitos obtenidos de bacterias extremófilas para la fabricación de medicamentos inhalables para la prevención y el tratamiento de enfermedades pulmonares y cardiovasculares, así como un dispositivo de inhalación que contiene osmolitos como componentes activos
CL2012000327A1 (es) Composicion farmaceutica resistente a corrosion y estable para inhalador presurizado de dosis medida que contiene un ingrediente activo suspendido y otro disuelto, un haluro disuelto, un cosolvente, un propulsor, entre 0,1 y 10 % de agua, 0,0001 y 0,01 % de un acido organico y 0,01 a 0,3 % de agente suspensor insaturado; metodo de preparacion.
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
AR038764A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
AR074470A1 (es) Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes
CO2024017482A2 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
TH86643A (th) สูตรผสมสารละลาย hfc ที่มีแซลบูทามอล ไฮโดรคลอไรด์ หรือ แซลบูทามอล ซิเทรท

Legal Events

Date Code Title Description
FA Abandonment or withdrawal